Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS
August 4, 2015 4:20 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) reported Q2 EPS of ($0.45), in-line with the analyst estimate of ($0.45). Revenue for the quarter came in at $161.6 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.
... More